Academia.eduAcademia.edu

Results of Data Analysis

2019, Personality Traits and Drug Consumption

This chapter includes results of data analysis. The relationship between personality profiles and drug consumption is described and the individual drug consumption risks for different drugs is evaluated. Significant differences between groups of drug users and non-users are identified. Machine learning algorithms solve the user/non-user classification problem for many drugs with impressive sensitivity and specificity. Analysis of correlations between use of different drugs reveals existence of clusters of substances with highly correlated use, which we term correlation pleiades. It is proven that the mean profiles of users of different drugs are significantly different (for benzodiazepines, ecstasy, and heroin). Visualisation of risk by risk maps is presented. The difference between users of different drugs is analysed and three distinct types of users are identified for benzodiazepines, ecstasy, and heroin. Keywords Risk analysis • Psychological profiles • Discriminant analysis • Correlation pleiades • Drug clustering 4.1 Descriptive Statistics and Psychological Profile of Illicit Drug Users The data set contains seven categories of drug users: 'Never used', 'Used over a decade ago', 'Used in last decade', 'Used in last year', 'Used in last month', 'Used in last week', and 'Used in last day'. A respondent selected their category for every drug from the list. We formed four classification problems based on the following classes (see section 'Drug use'): the decade-, year-, month-, and week-based user/non-user separations. We have identified the relationship between personality profiles (NEO-FFI-R) and drug consumption for the decade-, year-, month-, and week-based classification problems. We have evaluated the risk of drug consumption for each individual according to their personality profile. This evaluation was performed separately for each drug for the decade-based user/non-user separation. We have also analysed the interrelations between the individual drug consumption risks for different drugs. Part of these results has been presented in [1] (and in more detail in the 2015 technical